DDInter1961 DDInter1676
A dideoxynucleoside compound in which the 3&#39;-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluridine
Zidovudine {u} (Compound) resembles {v} (Compound) Idoxuridine
Zidovudine {u} (Compound) resembles {v} (Compound) Telbivudine
Zidovudine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Zidovudine {u} (Compound) binds {v} (Gene) UGT2B7
Zidovudine {u} (Compound) upregulates {v} (Gene) THAP11
Zidovudine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Reverse Transcriptase Inhibitors
Zidovudine {u} (Compound) downregulates {v} (Gene) MRPS16
Zidovudine {u} (Compound) causes {v} (Side Effect) Tremor
Zidovudine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine
Zidovudine (Compound) resembles Idoxuridine (Compound)
Zidovudine (Compound) resembles Telbivudine (Compound)
Zidovudine (Compound) treats acquired immunodeficiency syndrome (Disease)
Zidovudine (Compound) binds UGT2B7 (Gene)
Zidovudine (Compound) upregulates THAP11 (Gene)
Zidovudine (Compound) is included by Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Zidovudine (Compound) downregulates MRPS16 (Gene)
Zidovudine (Compound) causes Tremor (Side Effect)
Zidovudine may cause a minor interaction that can limit clinical effects when taken with Cimetidine